Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials

BACKGROUND: As a poly-ADP ribose polymerase (PARP) inhibitor, veliparib has been identified as a potential therapeutic agent for lung cancer. The present study aimed to conduct a systematic review of clinical trials investigating the efficacy and safety of veliparib for treating lung cancer. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Daei Sorkhabi, Amin, Fazlollahi, Asra, Sarkesh, Aila, Aletaha, Reza, Feizi, Hamidreza, Mousavi, Seyed Ehsan, Nejadghaderi, Seyed Aria, Sullman, Mark J. M., Kolahi, Ali-Asghar, Safiri, Saeid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10490931/
https://www.ncbi.nlm.nih.gov/pubmed/37682974
http://dx.doi.org/10.1371/journal.pone.0291044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10490931/
https://www.ncbi.nlm.nih.gov/pubmed/37682974
http://dx.doi.org/10.1371/journal.pone.0291044

Ejemplares similares